Clinical-stage biopharmaceutical company developing therapies for ocular cancers using viral nanoparticle technology.
Aura Biosciences, Inc. is a pioneering biotechnology firm focused on advancing innovative therapies for the treatment of cancer. Specializing in ocular and urologic oncology, the company utilizes its proprietary virus-like drug conjugates (VDC) technology platform to address tumors with significant unmet medical needs. At the forefront of its pipeline is AU-011, a promising VDC candidate developed specifically for treating primary choroidal melanoma, a rare and aggressive form of eye cancer.
In addition to its groundbreaking work with AU-011, Aura Biosciences is actively exploring the potential of its VDC technology in other ocular oncology indications, including choroidal metastases. This expansion underscores the company's commitment to leveraging scientific innovation to address diverse challenges within the field of oncology.
Established in 2009 and headquartered in Cambridge, Massachusetts, Aura Biosciences operates within one of the world's leading biotechnology hubs, facilitating access to top-tier talent and cutting-edge research capabilities. The company's strategic location supports its mission to pioneer novel cancer therapies that have the potential to transform patient outcomes and quality of life.
With a dedicated focus on advancing transformative treatments, Aura Biosciences continues to push the boundaries of biopharmaceutical innovation. Through its robust research and development efforts, strategic partnerships, and commitment to excellence, the company remains poised to make significant strides in the fight against cancer.